Siren, L.L.C.
Siren, L.L.C. reported 110 stocks worth $4.2B in its 13F filing for Q3 2026, filed Nov 12, 2026. Its largest holdings are SRRK (10.7%), KYMR (7.4%) and ERAS (4.6%). Compared with Q2 2026, the fund opened new positions in ADRX, ASND and DMRA, added to ERAS, TNGX and ARWR, trimmed SRRK, KYMR and RVMD and sold out of DFTX, COF and SION.
Latest filing: what Siren, L.L.C. did in Q3 2026
vs Q2 2026Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() SRRK Scholar Rock Hldg Corp | $453M | 10.7% | 9.4M | −200K (−2%) | 8 of 8 | |
| 2 | ![]() KYMR Kymera Therapeutics Inc | $311M | 7.4% | 2.8M | −151K (−5%) | 8 of 8 | |
| 3 | ![]() ERAS Erasca Inc | $193M | 4.6% | 13.2M | +1.8M (+16%) | 8 of 8 | |
| 4 | ![]() RVMD Revolution Medicines Inc | $174M | 4.1% | 850K | −50K (−6%) | 8 of 8 | |
| 5 | ![]() ONC Beone Medicines Ltd | $170M | 4.0% | 465K | No change | 8 of 8 | |
| 6 | ![]() TNGX Tango Therapeutics Inc | $169M | 4.0% | 6.8M | +605K (+10%) | 8 of 8 | |
| 7 | ![]() MANE Veradermics Inc | $161M | 3.8% | 1.3M | −331K (−20%) | 3 of 8 | |
| 8 | ![]() ARWR Arrowhead Pharmaceuticals in | $150M | 3.5% | 2.3M | +575K (+34%) | 8 of 8 | |
| 9 | ![]() EWTX Edgewise Therapeutics Inc | $114M | 2.7% | 2.8M | −380K (−12%) | 8 of 8 | |
| 10 | ![]() RYTM Rhythm Pharmaceuticals Inc | $103M | 2.5% | 1.1M | −50K (−4%) | 7 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
![]() DFTX Definium Therapeutics Inc | $66.8M | 1.4M |
CRINETICS PHARMACEUTICALS IN | $53.2M | 1.4M |
![]() COF Capital One Finl Corp | $34.4M | 172K |
![]() SION Sionna Therapeutics Inc | $26.9M | 611K |
![]() ORKA Oruka Therapeutics Inc | $23.8M | 250K |
🔒 Free account: see all 23.
Options
valued at the underlying shares| Stock | Type | Value | Shares | Change |
|---|---|---|---|---|
![]() MSFT Microsoft Corp | Call | $12.3M | 24K | 0 |
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 12, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Siren, L.L.C. 13F FAQ
What does Siren, L.L.C. own?
Siren, L.L.C. reported 110 stocks worth $4.2B in its 13F filing for Q3 2026, filed Nov 12, 2026. The table above lists every position in the filing (the top 10 without an account).
What did Siren, L.L.C. buy and sell in Q3 2026?
Compared with Q2 2026: 18 new positions, 17 added to, 37 trimmed and 23 sold out. New positions include ADRX, ASND and DMRA. It sold all of DFTX, COF and SION.
When will Siren, L.L.C. file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Siren, L.L.C.'s portfolio worth?
The Q3 2026 filing reports $4.2B in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.
























